BHP 01
Alternative Names: BHP-01; α-PD-L1/4-1BB DLL3 CAR-T - Chengdu Brilliant PharmaceuticalLatest Information Update: 19 Apr 2024
At a glance
- Originator Chengdu Brilliant Pharmaceutical
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Small cell lung cancer
Most Recent Events
- 05 Apr 2024 Preclinical trials in Small cell lung cancer in China (IV)
- 05 Apr 2024 Chengdu Brilliant Pharmaceutical plans a phase I trial for Small cell lung cancer (Second-line therapy or greater, Recurrent) (IV, Infusion) in June 2024 (NCT06348797)